IN2012DN03338A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03338A
IN2012DN03338A IN3338DEN2012A IN2012DN03338A IN 2012DN03338 A IN2012DN03338 A IN 2012DN03338A IN 3338DEN2012 A IN3338DEN2012 A IN 3338DEN2012A IN 2012DN03338 A IN2012DN03338 A IN 2012DN03338A
Authority
IN
India
Prior art keywords
factor
antibody
antigen binding
binding fragment
crystal structure
Prior art date
Application number
Other languages
English (en)
Inventor
Menno Van Lookeren Campagen
Christian Wiesmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2012DN03338A publication Critical patent/IN2012DN03338A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
IN3338DEN2012 2009-11-04 2010-11-04 IN2012DN03338A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28046009P 2009-11-04 2009-11-04
US28171609P 2009-11-20 2009-11-20
PCT/US2010/055509 WO2011057014A1 (en) 2009-11-04 2010-11-04 Co-crystal structure of factor d and anti-factor d antibody

Publications (1)

Publication Number Publication Date
IN2012DN03338A true IN2012DN03338A (pt) 2015-10-23

Family

ID=43303899

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3338DEN2012 IN2012DN03338A (pt) 2009-11-04 2010-11-04

Country Status (14)

Country Link
US (1) US20110165648A1 (pt)
EP (1) EP2496695A1 (pt)
JP (1) JP2013509866A (pt)
KR (1) KR20120120153A (pt)
CN (1) CN102666850A (pt)
AR (1) AR078886A1 (pt)
BR (1) BR112012011607A2 (pt)
CA (1) CA2782481A1 (pt)
IN (1) IN2012DN03338A (pt)
MX (1) MX2012005430A (pt)
RU (1) RU2012122700A (pt)
TW (1) TW201121993A (pt)
WO (1) WO2011057014A1 (pt)
ZA (1) ZA201202602B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
ES2819217T3 (es) 2013-09-08 2021-04-15 Kodiak Sciences Inc Conjugados de polímeros iónicos dipolares y factor VIII
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
EP3207128B1 (en) 2014-10-17 2022-07-27 Kodiak Sciences Inc. Butyrylcholinesterase zwitterionic polymer conjugates
TW201730211A (zh) 2015-10-30 2017-09-01 建南德克公司 抗因子d抗體及結合物
JP2018536650A (ja) 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
WO2017075259A1 (en) * 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody formulations
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
EP3405577B8 (en) 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions and methods for inhibiting factor d
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
CA3059938A1 (en) * 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
US6291160B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2118066T3 (es) 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
US5244800A (en) * 1990-04-27 1993-09-14 The Uab Research Foundation Crystals of human complement factor d that are triclinic
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
CN106084055A (zh) * 2006-11-02 2016-11-09 健泰科生物技术公司 人源化的抗‑d因子抗体
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) * 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados

Also Published As

Publication number Publication date
KR20120120153A (ko) 2012-11-01
US20110165648A1 (en) 2011-07-07
JP2013509866A (ja) 2013-03-21
CA2782481A1 (en) 2011-05-12
CN102666850A (zh) 2012-09-12
EP2496695A1 (en) 2012-09-12
ZA201202602B (en) 2013-06-26
WO2011057014A1 (en) 2011-05-12
RU2012122700A (ru) 2013-12-10
MX2012005430A (es) 2012-06-19
AR078886A1 (es) 2011-12-07
TW201121993A (en) 2011-07-01
BR112012011607A2 (pt) 2020-06-02

Similar Documents

Publication Publication Date Title
EP2566890A4 (en) ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE
CY1122978T1 (el) Αντισωματα εναντι-vla-4
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
MX340555B (es) Anticuerpos contra il-18r1 y usos de los mismos.
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
PH12013502230A1 (en) Multispecific antibodies
PH12013501339A1 (en) Anti-pcsk9 antibodies and methods of use
EA201201000A1 (ru) Способы лечения колоректального рака
HUE046564T2 (hu) XI-es faktor elleni monoklonális antitestek és eljárások az alkalmazásukra
CY1121167T1 (el) Βελτιωμενα αντισωματα εναντι της ανθρωπινης φρακταλκινης και χρησεις αυτων
PH12018500046A1 (en) Anti-mesothelin antibodies and immunoconjugates
UA107600C2 (uk) АНТИТІЛО ПРОТИ N3pGlu БЕТА-АМІЛОЇДНОГО ПЕПТИДУ ТА ЙОГО ЗАСТОСУВАННЯ
IN2014KN00848A (pt)
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado
MX336001B (es) Anticuerpos anti-axl y metodos de uso.
MY159398A (en) Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
MX336323B (es) Anticuerpos de anti-poliubiquitina y metodos de uso.
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
MX347454B (es) Anticuerpos monoclonales inhibidores anti-factor xii-xiia.
MX2011010012A (es) NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
IN2014DN05885A (pt)
PH12013500933A1 (en) Methods and compositions for neural disease immunotherapy
MY161868A (en) Anti-bv8 antibodies and uses thereof
EA201070179A1 (ru) Антиген, связанный с вариантами рака легкого и лимфомами